RSV(B)-Pre-F0

RSV(B)-Pre-F0 Product List

  • Product Category

    Antibody (3)

  • Product Status

    Launched (3)

  • Species

    Mouse (3)

  • Tag

    - (3)

  • Conjugate

    Unconjugated (3)

RSV(B)-Pre-F0 Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
NG-641EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAPPhase 1 ClinicalAkamis Bio Ltd, University Of OxfordSquamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis
Details
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland